TABLE 1.

Daptomycin susceptibility testing of clinical methicillin-resistant Staphylococcus aureus isolates

Isolate sourceSample typeDate of isolation (mo/day/yr)Disk zone size (mm)aMIC (μg/ml)b
Patient 1cTibial tissue12/31/03220.25
Synovial fluid12/31/03220.25
Blood1/2/04220.25
Blood1/2/04220.25
Blood1/7/04220.25
Blood1/7/04220.25
Blood1/8/04220.25
Blood1/8/04220.25
Blood1/9/04220.25
Blood1/9/04220.25
Blood2/12/04184
Epidural tissue2/18/04184
Patient 2dBlood12/9/03230.5
Blood3/3/04230.5
Blood3/5/04240.5
Blood3/7/04240.5
Blood3/11/04232
Blood5/2/04192
Blood5/2/04202
Blood5/3/04202
Blood5/4/04192
Blood5/6/04194
Blood5/7/04202
Blood5/9/04202
Blood5/11/04194
Blood5/11/04192
Blood5/13/04194
  • a Tested by the disk diffusion method.

  • b Tested by a microbroth dilution method.

  • c Daptomycin therapy started 9 January 2004.

  • d Daptomycin therapy started 13 March 2004.